Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

Welcome to Edition 8.32 of the Rocket Report! The big news this week is NASA’s shake-up of the Artemis program. On paper, at least, the changes appear to be quite sensible. Canceling the big, new ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 Earnings Call Transcript March 4, 2026 Sight Sciences, Inc. beats earnings expectations. Reported EPS is $-0.07841, expectations were $-0.15. Operator: Good ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...